Director, Value & Evidence Strategy

This role is considered Hybrid.

Overview

The Director, Value Demonstration will play a pivotal role in shaping the future of Alnylam by driving the generation of robust, real-world evidence (RWE) to support the value proposition of our innovative products.  This position will serve as a subject matter expert on RWE generation using diverse data sources, including administrative databases, electronic health and medical records (EHR/EMR), and other observational data.  You will collaborate closely with key stakeholders across the organization, including International Market Access, Country Medical Directors, and Global HEOR, to develop and execute impactful RWE studies that address critical clinical and economic questions.

Key Responsibilities

• Strategic Leadership:  Contribute to the development and execution of a comprehensive RWE strategy aligned with the company’s overall business objectives.
• RWE Expertise:  Serve as a subject matter expert and RWE methodologies, data sources, and analytical techniques.
• Cross-Functional Collaboration:  Collaborate closely with Market Access, Medical Affairs, HEOR, and other expertise areas to identify RWE opportunities and integrate RWE findings into value dossiers and presentations.
• Study Design and Execution:  Design, develop, and oversee the execution of RWE studies, including protocol development, data acquisition, analysis, and interpretation, ensuring the application of rigorous study design and statistical methods and robust data quality.
• External Engagement:  Engage with key opinion leaders, academic institutions, and industry partners to advance the field of RWE and foster collaborations.

Qualifications

• Doctoral degree (PhD, DrPH, ScD) in health services research, epidemiology, health economics, or related field with 4+ years professional experience in study design, research methodology, and statistical analysis in a pharmaceutical/biotech, consulting, healthcare, academic or research setting
• Master’s degree with 7+ years professional experience in study design, research methodology, and statistical analysis in a pharmaceutical/biotech, consulting, healthcare, academic or research setting
• Strong understanding of regulatory requirements and guidelines related to RWE
• Excellent communication and presentation skills, both written and oral
• Experience in communicating technical data both internally and externally to non-technical audiences
• Proficiency in statistical software (e.g., SAS, R, Python) and data analysis tools
• Experience with large-scale observational databases (e.g., claims databases, EHR/EMR data)
• Knowledge of health economics and outcomes research (HEOR) principles
• Ability to work independently and collaboratively with multidisciplinary groups

Desired Capabilities, Experience, and Training:

• Pharmaceutical industry and/or consulting experience, with a focus on HEOR, market access, or medical affairs
• Familiarity with RWE platforms and tools
• Experience with US and international real-world data sources and procedures
• Experience with international regulatory requirements and guidelines

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.